Densitas, based in Halifax, NS, develops advanced breast imaging analytics technologies powered by machine learning to deliver on‑demand actionable insights for breast health management. The company was one of eight Canadian healthtech firms to receive venture investments in MedTeq’s initial co-investment activity. Those investments are intended to help mature technologies, accelerate innovation, and de-risk companies as they commercialize. Densitas’s participation in the round links it to investors focused on scaling early-stage healthtech across Canada. The article does not disclose Densitas’s individual raise size or operating metrics, but notes the group of eight companies collectively raised $11 million. MedTeq and its co-investors aim to address procurement barriers that have hindered commercialization of digital health products, which could affect Densitas’s go-to-market pathway. Densitas is an ISO-certified software medical device company that develops digital mammography products using imaging analytics technologies. Its core product, DM-Density, is an adjunctive tool radiologists use when reviewing mammograms to determine breast density. The company was founded in 2011 by CEO Mohamed Abdolell and is based in Halifax, Nova Scotia, Canada. Densitas secured $250k in funding from Innovacorp as part of a larger, undisclosed round with participation from private investors. The company intends to use the funds to continue to bring its products to market. The financing is positioned to support commercialization and market entry of its imaging analytics offerings.

Total raised

$11M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2019